Stempoint Capital LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), Stempoint Capital LP reported 42 stock positions worth $339.9 million. Its top holding was Syndax Pharmaceuticals (SNDX) at 8.5% of the portfolio, followed by Roivant Sciences (ROIV, 8.4%) and Immunovant (IMVT, 7.9%). Compared with Q1 2024, it opened 16 new positions, sold out of 19, added to 14 and reduced 10. The biggest buy was a new position in Immunocore Holdings PLC-ADR (IMCR) and the biggest sale Arcutis Biotherapeutics (ARQT, shares −56%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001952142
- Portfolio Value
- $339.9M (Q2 2024)
- SEC Filing
- 0001420506-24-001418 ↗ filed Aug 13, 2024
Holdings Value
Holdings 42 stocks · $339.9M
| SNDX Syndax Pharmaceuticals Inc. | 8.53% | 1,412,176 | $29.0M | Add +28.3% |
| ROIV Roivant Sciences Ltd. | 8.44% | 2,712,741 | $28.7M | Reduce -23.7% |
| IMVT Immunovant Inc. | 7.86% | 1,011,879 | $26.7M | Add +61.3% |
| CRNX Crinetics Pharmaceuticals Inc. | 7.26% | 551,095 | $24.7M | Reduce -11.1% |
| MRUS Merus NV | 5.02% | 288,668 | $17.1M | Add +23.4% |
| ACLX Arcellx Inc. | 4.56% | 280,709 | $15.5M | Add +100.1% |
| FOLD Amicus Therapeutics Inc. | 4.36% | 1,495,047 | $14.8M | Reduce -3.4% |
| IMCR Immunocore Holdings PLC-ADR | 3.38% | 339,351 | $11.5M | New |
| APLT Applied Therapeutics Inc. | 3.04% | 2,211,320 | $10.3M | Add +9.6% |
| MRK Merck & Co. Inc. | 2.99% | 81,508 | $10.2M | New |
| GSK GSK PLC-Spon ADR | 2.79% | 245,933 | $9.5M | New |
| AUTL Autolus Therapeutics PLC | 2.73% | 2,662,732 | $9.3M | Reduce -10.2% |
| ARQT Arcutis Biotherapeutics Inc. | 2.64% | 965,392 | $9.0M | Reduce -56.2% |
| CABA Cabaletta Bio Inc. | 2.59% | 1,178,105 | $8.8M | Add +17.4% |
| KALV Kalvista Pharmaceuticals Inc. | 2.55% | 736,765 | $8.7M | Reduce -36.5% |
| BHVN Biohaven Ltd. | 2.38% | 233,255 | $8.1M | Add +179.5% |
| VTGN Vistagen Therapeutics Inc. | 1.72% | 1,848,582 | $5.8M | No change |
| IMTX Immatics NV | 1.72% | 502,207 | $5.8M | Add +2.1% |
| DNLI Denali Therapeutics Inc. | 1.71% | 251,010 | $5.8M | New |
| INSM Insmed Inc. | 1.71% | 86,980 | $5.8M | Reduce -68.1% |
| CLDX Celldex Therapeutics Inc. | 1.57% | 144,467 | $5.3M | New |
| LRMR Larimar Therapeutics Inc. | 1.50% | 704,349 | $5.1M | Reduce -4.9% |
| TCRX Tscan Therapeutics Inc. | 1.45% | 845,069 | $4.9M | New |
| EWTX Edgewise Therapeutics Inc. | 1.44% | 271,057 | $4.9M | New |
| CRBP Corbus Pharmaceuticals Holdi | 1.35% | 101,479 | $4.6M | New |
| FULC Fulcrum Therapeutics Inc. | 1.27% | 696,464 | $4.3M | Add +71.1% |
| NRIX Nurix Therapeutics Inc. | 1.25% | 203,273 | $4.2M | New |
| PYXS Pyxis Oncology Inc. | 1.17% | 1,202,675 | $4.0M | Reduce -33.0% |
| JANX Janux Therapeutics Inc. | 1.15% | 92,949 | $3.9M | Reduce -23.6% |
| IDYA Ideaya Biosciences Inc. | 1.05% | 101,787 | $3.6M | Add +16.5% |
| SYRE Spyre Therapeutics Inc. | 1.04% | 150,450 | $3.5M | Add +141.7% |
| CATX Perspective Therapeutics Inc. | 1.01% | 343,810 | $3.4M | New |
| JSPR Jasper Therapeutics Inc. | 0.96% | 143,775 | $3.3M | Add +11.3% |
| BDTX Black Diamond Therapeutics I | 0.92% | 674,198 | $3.1M | New |
| VIGL Vigil Neuroscience Inc. | 0.88% | 744,412 | $3.0M | New |
| NGNE Neurogene Inc. | 0.84% | 78,601 | $2.9M | New |
| SLN Silence Therapeutics PLC-ADR | 0.70% | 124,866 | $2.4M | New |
| TARA Protara Therapeutic Inc. | 0.60% | 984,113 | $2.0M | Add +484.2% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.60% | 200,000 | $2.0M | No change |
| SRZN Surrozen Inc. | 0.46% | 143,510 | $1.6M | New |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.44% | 150,000 | $1.5M | New |
| PRAX Praxis Precision Medicines I | 0.36% | 29,259 | $1.2M | Add +8.8% |
Options reported separately and not counted above: ARQT calls ($350K).
Portfolio Sells Q1 2024 → Q2 2024
| ARQT Arcutis Biotherapeutics Inc. | Reduce -56.2% | 2.64% | −3.20 |
| LLY Eli Lilly & Co. | Sold out | 0.00% | −3.13 |
| AUTL Autolus Therapeutics PLC | Reduce -10.2% | 2.73% | −2.33 |
| TARS Tarsus Pharmaceuticals Inc. | Sold out | 0.00% | −2.16 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −1.68 |
| ANAB Anaptysbio Inc. | Sold out | 0.00% | −1.62 |
| ROIV Roivant Sciences Ltd. | Reduce -23.7% | 8.44% | −1.57 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −1.32 |
| SLRN Acelyrin Inc. | Sold out | 0.00% | −1.29 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −1.22 |
| ANNX Annexon Inc. | Sold out | 0.00% | −1.16 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -36.5% | 2.55% | −1.13 |
| AVDL Avadel Pharmaceuticals Ltd. | Sold out | 0.00% | −1.01 |
| IRON Disc Medicine Inc. | Sold out | 0.00% | −1.00 |
| PYXS Pyxis Oncology Inc. | Reduce -33.0% | 1.17% | −0.87 |
| TSHA Taysha Gene Therapies Inc. | Sold out | 0.00% | −0.83 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −0.72 |
| EFTR Effector Therapeutics Inc. | Sold out | 0.00% | −0.51 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −0.51 |
| FOLD Amicus Therapeutics Inc. | Reduce -3.4% | 4.36% | −0.51 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -11.1% | 7.26% | −0.49 |
| CGON CG Oncology Inc. | Sold out | 0.00% | −0.48 |
| ACHL Achilles Therapeutics PL-ADR | Sold out | 0.00% | −0.46 |
| DNTH Dianthus Therapeutics Inc. | Sold out | 0.00% | −0.35 |
| CRGX Cargo Therapeutics Inc. | Sold out | 0.00% | −0.30 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −0.27 |
| INSM Insmed Inc. | Reduce -68.1% | 1.71% | −0.26 |
| JANX Janux Therapeutics Inc. | Reduce -23.6% | 1.15% | −0.08 |
| LRMR Larimar Therapeutics Inc. | Reduce -4.9% | 1.50% | −0.00 |
Portfolio Buys Q1 2024 → Q2 2024
| IMCR Immunocore Holdings PLC-ADR | New | 3.38% | +3.38 |
| MRK Merck & Co. Inc. | New | 2.99% | +2.99 |
| GSK GSK PLC-Spon ADR | New | 2.79% | +2.79 |
| IMVT Immunovant Inc. | Add +61.3% | 7.86% | +2.44 |
| MRUS Merus NV | Add +23.4% | 5.02% | +2.21 |
| ACLX Arcellx Inc. | Add +100.1% | 4.56% | +1.95 |
| DNLI Denali Therapeutics Inc. | New | 1.71% | +1.71 |
| CLDX Celldex Therapeutics Inc. | New | 1.57% | +1.57 |
| SNDX Syndax Pharmaceuticals Inc. | Add +28.3% | 8.53% | +1.53 |
| TCRX Tscan Therapeutics Inc. | New | 1.45% | +1.45 |
| EWTX Edgewise Therapeutics Inc. | New | 1.44% | +1.44 |
| CRBP Corbus Pharmaceuticals Holdi | New | 1.35% | +1.35 |
| NRIX Nurix Therapeutics Inc. | New | 1.25% | +1.25 |
| BHVN Biohaven Ltd. | Add +179.5% | 2.38% | +1.16 |
| CATX Perspective Therapeutics Inc. | New | 1.01% | +1.01 |
| BDTX Black Diamond Therapeutics I | New | 0.92% | +0.92 |
| VIGL Vigil Neuroscience Inc. | New | 0.88% | +0.88 |
| NGNE Neurogene Inc. | New | 0.84% | +0.84 |
| SLN Silence Therapeutics PLC-ADR | New | 0.70% | +0.70 |
| SRZN Surrozen Inc. | New | 0.46% | +0.46 |
| FRNM Freenome Inc. | New | 0.44% | +0.44 |
| TARA Protara Therapeutic Inc. | Add +484.2% | 0.60% | +0.42 |
| SYRE Spyre Therapeutics Inc. | Add +141.7% | 1.04% | +0.41 |
| IMTX Immatics NV | Add +2.1% | 1.72% | +0.34 |
| FULC Fulcrum Therapeutics Inc. | Add +71.1% | 1.27% | +0.24 |
| IDYA Ideaya Biosciences Inc. | Add +16.5% | 1.05% | +0.03 |
| JSPR Jasper Therapeutics Inc. | Add +11.3% | 0.96% | −0.05 |
| PRAX Praxis Precision Medicines I | Add +8.8% | 0.36% | −0.08 |
| APLT Applied Therapeutics Inc. | Add +9.6% | 3.04% | −0.63 |
| CABA Cabaletta Bio Inc. | Add +17.4% | 2.59% | −1.98 |
Options Activity Q1 2024 → Q2 2024
| CABA Cabaletta Bio Inc. | put | Sold out | 500,000 | $1.1Mbefore exit |
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 1,200,000 | $876Kbefore exit |
| ARQT Arcutis Biotherapeutics Inc. | put | Sold out | 825,000 | $516Kbefore exit |
| ARQT Arcutis Biotherapeutics Inc. | call | New | 500,000 | $350K |
| IMVT Immunovant Inc. | call | Sold out | 250,000 | $319Kbefore exit |
| MRUS Merus NV | put | Sold out | 85,000 | $213Kbefore exit |
| RNAM Avidity Biosciences Inc. | call | Sold out | 75,000 | $184Kbefore exit |
| CRNX Crinetics Pharmaceuticals Inc. | put | Sold out | 175,000 | $158Kbefore exit |
| ACLX Arcellx Inc. | put | Sold out | 50,000 | $135Kbefore exit |
| BHVN Biohaven Ltd. | put | Sold out | 30,000 | $122Kbefore exit |
| FOLD Amicus Therapeutics Inc. | call | Sold out | 400,000 | $120Kbefore exit |
| VERA Vera Therapeutics Inc. | put | Sold out | 40,000 | $75Kbefore exit |
| KRYS Krystal Biotech Inc. | put | Sold out | 20,000 | $71Kbefore exit |
| AUTL Autolus Therapeutics PLC | call | Sold out | 250,000 | $69Kbefore exit |
| ROIV Roivant Sciences Ltd. | put | Sold out | 750,000 | $56Kbefore exit |
| TARS Tarsus Pharmaceuticals Inc. | put | Sold out | 50,000 | $41Kbefore exit |
| TARA Protara Therapeutic Inc. | call | Sold out | 87,900 | $13Kbefore exit |
| UTHR United Therapeutics Corp. | call | Sold out | 10,000 | $11Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 73 | $577.9M | TNGX, ABVX, RVMD, ERAS, TYRA |
| Q1 2026Amended | 70 | $520.3M | SRRK, ABVX, SNDX, RVMD, IMVT |
| Q4 2025 | 75 | $582.7M | ABVX, SRRK, CNTA, SNDX, GPCR |
| Q3 2025 | 76 | $495.9M | ROIV, QURE, SRRK, IMVT, DNLI |
| Q2 2025 | 50 | $310.6M | SNDX, IMVT, SRRK, CNTA, MDGL |
| Q1 2025 | 52 | $313.1M | ROIV, SNDX, SRRK, ACLX, MRUS |
| Q4 2024 | 48 | $398.7M | SNDX, ROIV, IMVT, MRUS, CRNX |
| Q3 2024 | 50 | $333.4M | SNDX, ROIV, MRUS, IMVT, ARQT |
| Q2 2024Amended | 42 | $339.9M | SNDX, ROIV, IMVT, CRNX, MRUS |
| Q1 2024Amended | 45 | $374.3M | ROIV, CRNX, SNDX, ARQT, IMVT |